PubMed=12532417; DOI=10.1002/ijc.10917
Rouslan Kotchetkov, Jaroslaw Cinatl, Roman A. Blaheta, Jens-Uwe Vogel, Jana Karaskova, Jeremy Andrew Squire, Pablo Hernaiz Driever, Thomas Klingebiel, Jindrich Cinatl Jr.;
Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model.
Int. J. Cancer 104:36-43(2003)

PubMed=16151587
Jiri B. Bedrnicek, Ales Vicha, Marie Jarosova, Milena Holzerova, Jindrich Cinatl Jr., Martin Michaelis, Jaroslaw Cinatl, Tomas Eckschlager;
Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.
Neoplasma 52:415-419(2005)

PubMed=17505515; DOI=10.1038/sj.bjc.6603777; PMCID=PMC2359931
Roman A. Blaheta, Martin Michaelis, Iyad Natsheh, Christoph Hasenberg, Eva Weich, Borna Relja, Dietger Jonas, Hans-Wilhelm Doerr, Jindrich Cinatl Jr.;
Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium.
Br. J. Cancer 96:1699-1706(2007)

PubMed=22170099; DOI=10.1038/cddis.2011.129; PMCID=PMC3252738
Martin Michaelis, Florian Rothweiler, Susanne Barth, Jaroslaw Cinatl, Marijke van Rikxoort, Nadine Loschmann, Yvonne Voges, Rainer Breitling, Andreas von Deimling, Franz Rodel, Kristoffer Weber ...Show all 17 authors... , Boris Fehse, Elisabeth Mack, Thorsten Stiewe, Hans-Wilhelm Doerr, Daniel Speidel, Jindrich Cinatl Jr.; Show fewer authors
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
Cell Death Dis. 2:e243.1-e243.8(2011)

PubMed=25749379; DOI=10.18632/oncotarget.2889; PMCID=PMC4627332
Martin Michaelis, Florian Rothweiler, Nadine Loschmann, Mohsen Sharifi, Taravat Ghafourian, Jindrich Cinatl Jr.;
Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.
Oncotarget 6:17605-17620(2015)